Show simple item record

resumen

Abstract
Modified vaccinia Ankara virus (MVA) is extensively used as a vaccine vector. We have previously observed that MVAΔ008, an MVA lacking the gene that codes for interleukin-18 binding protein, significantly increases CD8+ and CD4+ T-cell responses to vaccinia virus (VACV) epitopes and recombinant HIV antigens. However, the efficacy of this vector against pathogens or tumor cells remains unclear. Thus, the aim of this study was to evaluate the cellular [ver mas...]
dc.contributor.authorDel Medico Zajac, Maria Paula
dc.contributor.authorMolinari, Maria Paula
dc.contributor.authorGravisaco, María José
dc.contributor.authorMaizon, Daniel Omar
dc.contributor.authorMoron, Victor Gabriel
dc.contributor.authorGherardi, Maria Magdalena
dc.contributor.authorCalamante, Gabriela
dc.date.accessioned2021-11-15T14:24:41Z
dc.date.available2021-11-15T14:24:41Z
dc.date.issued2021-11
dc.identifier.issn0161-5890
dc.identifier.otherhttps://doi.org/10.1016/j.molimm.2021.08.004
dc.identifier.urihttp://hdl.handle.net/20.500.12123/10777
dc.identifier.urihttps://www.sciencedirect.com/science/article/abs/pii/S016158902100242X
dc.description.abstractModified vaccinia Ankara virus (MVA) is extensively used as a vaccine vector. We have previously observed that MVAΔ008, an MVA lacking the gene that codes for interleukin-18 binding protein, significantly increases CD8+ and CD4+ T-cell responses to vaccinia virus (VACV) epitopes and recombinant HIV antigens. However, the efficacy of this vector against pathogens or tumor cells remains unclear. Thus, the aim of this study was to evaluate the cellular immune response and the protection induced by recombinant MVAs encoding the model antigen ovalbumin (OVA). We used the MO5 melanoma tumor model (OVA-expressing tumor) as an approach for evaluating the vector-induced efficacy. Our results show that MVAΔ008-OVA (optimized vector) induced higher in vivo specific cytotoxicity and ex vivo T-cell IFN-γ responses against OVA than the conventional MVA vector. Importantly, the recombinant vectors were capable of controlling MO5 tumor growth. Indeed, the administration of MVAΔ008-OVA or MVA-OVA in prophylactic and therapeutic schemes provided total protection and longer survival of mice, respectively. Overall, our results demonstrate the improved immunogenicity and the protective capacity of MVAΔ008 against a heterologous model antigen. These findings suggest that MVAΔ008 constitutes an excellent candidate for vaccine development against pathogens or cancer therapy.eng
dc.formatapplication/pdfes_AR
dc.language.isoenges_AR
dc.publisherElsevieres_AR
dc.relationinfo:eu-repograntAgreement/INTA/PNBIO-1131032/AR./Desarrollo de herramientas biotecnológicas para la prevención y el control de enfermedades pecuarias: vacunas, diagnóstico y eIdemiología molecular.es_AR
dc.rightsinfo:eu-repo/semantics/restrictedAccesses_AR
dc.sourceMolecular Immunology 139 : 115-122 (November 2021)es_AR
dc.subjectVacunaes_AR
dc.subjectVaccineseng
dc.subjectVectoreses_AR
dc.subjectVectorseng
dc.subjectRespuesta Inmunológicaes_AR
dc.subjectImmune Responseeng
dc.subjectGenéticaes_AR
dc.subjectGeneticseng
dc.titleMVAΔ008 viral vector encoding the model protein OVA induces improved immune response against the heterologous antigen and equal levels of protection in a mice tumor model than the conventional MVAes_AR
dc.typeinfo:ar-repo/semantics/artículoes_AR
dc.typeinfo:eu-repo/semantics/articlees_AR
dc.typeinfo:eu-repo/semantics/publishedVersiones_AR
dc.description.origenInstituto de Biotecnologíaes_AR
dc.description.filFil: Del Medico Zajac, Maria Paula. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Biotecnología; Argentinaes_AR
dc.description.filFil: Del Medico Zajac, Maria Paula. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentinaes_AR
dc.description.filFil: Molinari, Maria Paula. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Biotecnología; Argentinaes_AR
dc.description.filFil: Molinari, Maria Paula. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentinaes_AR
dc.description.filFil: Gravisaco, Marí­a José. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Biotecnología; Argentinaes_AR
dc.description.filFil: Gravisaco, Marí­a José. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentinaes_AR
dc.description.filFil: Maizon, Daniel Omar Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Anguil; Argentinaes_AR
dc.description.filFil: Moron, Victor Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; Argentinaes_AR
dc.description.filFil: Moron, Victor Gabriel. Universidad Nacional de Córdoba.Facultad de Ciencias Químicas. Centro de Investigaciones en Bioquímica Clínica e Inmunología; Argentinaes_AR
dc.description.filFil: Gherardi, Maria Magdalena. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentinaes_AR
dc.description.filFil: Gherardi, Maria Magdalena. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina.es_AR
dc.description.filFil: Calamante, Gabriela. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Biotecnología; Argentinaes_AR
dc.description.filFil: Calamante, Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentinaes_AR
dc.subtypecientifico


Files in this item

Thumbnail

This item appears in the following Collection(s)

common

Show simple item record